Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3035817 | 0.90 | LMNA (0.47) | KDM4EKMT2ASMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL3039123 | 0.86 | SCD (0.58) | PPARAPPARDSCD | |
| SCHEMBL3035213 | 0.85 | PPARA (0.50) | PPARAPPARDSCDGAAPOLB | |
| SCHEMBL3048569 | 0.83 | SMN1; SMN2 (0.43) | TARBP2KDM4EKMT2ASMN1; SMN2PPARA | |
| SCHEMBL13137802 | 0.83 | SCD (0.55) | KDM4EKMT2ASMN1; SMN2PPARASCD | |
| SCHEMBL3842367 | 0.77 | GAA (0.41) | KMT2ASMN1; SMN2PPARASCDRAB9A | |
| SCHEMBL3046039 | 0.75 | TARBP2 (0.47) | TARBP2KDM4EKMT2ASMN1; SMN2PPARA | |
| SCHEMBL3035052 | 0.74 | CDC7 (0.50) | KDM4EKMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3038900 | 0.73 | PPARA (0.53) | PPARAPPARDSCDPOLB | |
| SCHEMBL3040893 | 0.72 | SCD (0.60) | SMN1; SMN2PPARAPPARDSCDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | claimed |
| EP-2086970-A2 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | Novartis AG (CH) | 2009-08-12 | — | — | EP | claimed |
| WO-2008024390-A2 | 2- (PYRAZIN-2-YL) -THIAZOLE AND 2- (1H-PYRAZ0L-3-YL) -THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | claimed |
| EP-2086970-B1 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8314138-B2 | Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20100239520-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-2086970-A2 | 2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | Novartis AG (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008024390-A2 | 2- (PYRAZIN-2-YL) -THIAZOLE AND 2- (1H-PYRAZ0L-3-YL) -THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239520-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | TARBP2 2791/4885KDM4E 683/4885KMT2A 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.